Lisata Therapeutics, Inc. (LSTA)

Market Cap	22.43M
Revenue (ttm)	n/a
Net Income (ttm)	-20.84M
Shares Out	8.31M
EPS (ttm)	-2.58
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	1,829
Open	2.750
Previous Close	2.670
Day's Range	2.670 - 2.870
52-Week Range	1.950 - 4.530
Beta	1.07
Analysts	Strong Buy
Price Target	15.00 (+455.56%)
Earnings Date	May 7, 2024

About LSTA

Lisata Therapeutics, Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of innovative therapies for the treatment of solid tumors and other diseases. Its product candidates include LSTA1, which is in Phase 2a and 2b clinical studies for the treatment of solid tumor, including metastatic pancreatic ductal adenocarcinoma (mPDAC), in combination with a range of anti-cancer regimens; XOWNA that is in Phase IIa clinical trial for the treatment of coronary microvascular dysfunction; and CD34+ c...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 1980
• Employees: 25
• Stock Exchange: NASDAQ
• Ticker Symbol: LSTA

Analyst Forecast

According to one analyst, the rating for LSTA stock is "Strong Buy" and the 12-month stock price forecast is $15.0.

Price Target

$15.0

(455.56% upside)

Analyst Consensus: Strong Buy